menu search

DRMA / Dermata (DRMA) Gains on Positive FDA Response for Acne Candidate

Dermata (DRMA) Gains on Positive FDA Response for Acne Candidate
Dermata (DRMA) gains on positive FDA response for the further development of DMT310 for treating severe to moderate acne. Read More
Posted: Apr 21 2023, 13:43
Author Name: Zacks Investment Research
Views: 102287

DRMA News  

Dermata Therapeutics to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and hosted by M-Vest on Tuesday, June 20th to Thursday, June 22nd at 9:00 A.M. ET

By Accesswire
June 13, 2023

Dermata Therapeutics to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and hosted by M-Vest on Tuesday, June 20th to Thursday, June 22nd at 9:00 A.M. ET

SAN DIEGO, CA / ACCESSWIRE / June 13, 2023 / Dermata Therapeutics, Inc. (NASDAQ:DRMA, DRMAW) ("Dermata" or the "Company"), a clinical-stage biotechnol more_horizontal

Dermata (DRMA) Gains on Positive FDA Response for Acne Candidate

By Zacks Investment Research
April 21, 2023

Dermata (DRMA) Gains on Positive FDA Response for Acne Candidate

Dermata (DRMA) gains on positive FDA response for the further development of DMT310 for treating severe to moderate acne. more_horizontal

Why Is Dermata Therapeutics (DRMA) Stock Up 22% Today?

By InvestorPlace
April 20, 2023

Why Is Dermata Therapeutics (DRMA) Stock Up 22% Today?

Dermata Therapeutics (NASDAQ: DRMA ) stock is on the rise Thursday following an update concerning its moderate-to-severe acne treatment. The big news more_horizontal

Trading Penny Stocks in the New Year? 3 Tips

By PennyStocks
January 3, 2023

Trading Penny Stocks in the New Year? 3 Tips

Which penny stocks are you buying this year? The post Trading Penny Stocks in the New Year? more_horizontal

Dermata Therapeutics Shares Plunge 20% Premarket: What Investors Need To Know

By Benzinga
February 7, 2022

Dermata Therapeutics Shares Plunge 20% Premarket: What Investors Need To Know

Dermata Therapeutics Inc  DRMA has requested the FDA to waive the requirements to complete a 90-day dermal minipig study and a standard dermal phar more_horizontal

Dermata Therapeutics Shares Plunge 20% Premarket: What Investors Need To Know

By Benzinga
February 7, 2022

Dermata Therapeutics Shares Plunge 20% Premarket: What Investors Need To Know

Dermata Therapeutics Inc  DRMA has requested the FDA to waive the requirements to complete a 90-day dermal minipig study and a standard dermal phar more_horizontal

Dermata Therapeutics Shares Plunge 20% Premarket: What Investors Need To Know

By Benzinga
February 7, 2022

Dermata Therapeutics Shares Plunge 20% Premarket: What Investors Need To Know

Dermata Therapeutics Inc  DRMA has requested the FDA to waive the requirements to complete a 90-day dermal minipig study and a standard dermal phar more_horizontal

Dermata Therapeutics (DRMA) Stock: Why The Price Substantially Fell Today

By Pulse2
February 7, 2022

Dermata Therapeutics (DRMA) Stock: Why The Price Substantially Fell Today

The stock price of Dermata Therapeutics Inc (NASDAQ: DRMA) fell by over 15% pre-market today. This is why it happened. more_horizontal


Search within

Pages Search Results: